Global Biosimilars of Rituximab Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
Table of Contents1 Report Overview
1.1 Research Scope
1.2 Market Segment by Type
1.2.1 Global Biosimilars of Rituximab Market Size Growth Rate by Type (2017 VS 2021 VS 2028)
1.2.2 500mg
1.2.3 100mg
1.2.4 Other
1.3 Market Segment by Application
1.3.1 Global Biosimilars of Rituximab Market Share by Application (2017 VS 2021 VS 2028)
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Biosimilars of Rituximab Market Size (2017-2028)
2.1.1 Global Biosimilars of Rituximab Revenue (2017-2028)
2.1.2 Global Biosimilars of Rituximab Sales (2017-2028)
2.2 Global Biosimilars of Rituximab Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.2.1 Global Biosimilars of Rituximab Sales by Regions (2017-2022)
2.2.2 Global Biosimilars of Rituximab Revenue by Regions (2017-2022)
2.3 Global Biosimilars of Rituximab Market Size Forecast by Region
2.3.1 Global Biosimilars of Rituximab Sales Forecast by Region (2023-2028)
2.3.2 Global Biosimilars of Rituximab Revenue Forecast by Region (2023-2028)
2.4 Global Top Biosimilars of Rituximab Regions (Countries) Ranking by Market Size
2.5 Biosimilars of Rituximab Market Dynamics
2.5.1 Biosimilars of Rituximab Market Trends
2.5.2 Biosimilars of Rituximab Market Drivers
2.5.3 Biosimilars of Rituximab Market Challenges
2.5.4 Biosimilars of Rituximab Market Restraints
3 Competitive Landscape by Manufacturers
3.1 Global Top Biosimilars of Rituximab Manufacturers by Sales (2017-2022)
3.1.1 Global Biosimilars of Rituximab Sales by Manufacturers (2017-2022)
3.1.2 Global Biosimilars of Rituximab Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global 5 and 10 Largest Manufacturers by Biosimilars of Rituximab Sales in 2021
3.2 Global Top Manufacturers Biosimilars of Rituximab by Revenue
3.2.1 Global Biosimilars of Rituximab Revenue by Manufacturers (2017-2022)
3.2.2 Top Biosimilars of Rituximab Manufacturers Covered: Ranking by Revenue
3.2.3 Global Biosimilars of Rituximab Revenue Share by Manufacturers (2017-2022)
3.2.4 Global Biosimilars of Rituximab Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Biosimilars of Rituximab as of 2021)
3.4 Global Biosimilars of Rituximab Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Biosimilars of Rituximab Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Biosimilars of Rituximab Market
3.7 Key Manufacturers Biosimilars of Rituximab Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Biosimilars of Rituximab Market Size by Type
4.1 Global Biosimilars of Rituximab Historic Market Review by Type (2017-2022)
4.1.1 Global Biosimilars of Rituximab Sales Market Share by Type (2017-2022)
4.1.2 Global Biosimilars of Rituximab Revenue Market Share by Type (2017-2022)
4.1.3 Biosimilars of Rituximab Price by Type (2017-2022)
4.2 Global Biosimilars of Rituximab Market Estimates and Forecasts by Type (2023-2028)
4.2.1 Global Biosimilars of Rituximab Sales Forecast by Type (2023-2028)
4.2.2 Global Biosimilars of Rituximab Revenue Forecast by Type (2023-2028)
4.2.3 Biosimilars of Rituximab Price Forecast by Type (2023-2028)
5 Global Biosimilars of Rituximab Market Size by Application
5.1 Global Biosimilars of Rituximab Historic Market Review by Application (2017-2022)
5.1.1 Global Biosimilars of Rituximab Sales Market Share by Application (2017-2022)
5.1.2 Global Biosimilars of Rituximab Revenue Market Share by Application (2017-2022)
5.1.3 Biosimilars of Rituximab Price by Application (2017-2022)
5.2 Global Biosimilars of Rituximab Market Estimates and Forecasts by Application (2023-2028)
5.2.1 Global Biosimilars of Rituximab Sales Forecast by Application (2023-2028)
5.2.2 Global Biosimilars of Rituximab Revenue Forecast by Application (2023-2028)
5.2.3 Biosimilars of Rituximab Price Forecast by Application (2023-2028)
6 North America
6.1 North America Biosimilars of Rituximab Sales Breakdown by Company
6.1.1 North America Biosimilars of Rituximab Sales by Company (2017-2022)
6.1.2 North America Biosimilars of Rituximab Revenue by Company (2017-2022)
6.2 North America Biosimilars of Rituximab Market Size by Type
6.2.1 North America Biosimilars of Rituximab Sales by Type (2017-2028)
6.2.2 North America Biosimilars of Rituximab Revenue by Type (2017-2028)
6.3 North America Biosimilars of Rituximab Market Size by Application
6.3.1 North America Biosimilars of Rituximab Sales by Application (2017-2028)
6.3.2 North America Biosimilars of Rituximab Revenue by Application (2017-2028)
6.4 North America Biosimilars of Rituximab Market Size by Country
6.4.1 North America Biosimilars of Rituximab Sales by Country (2017-2028)
6.4.2 North America Biosimilars of Rituximab Revenue by Country (2017-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Biosimilars of Rituximab Sales Breakdown by Company
7.1.1 Europe Biosimilars of Rituximab Sales by Company (2017-2022)
7.1.2 Europe Biosimilars of Rituximab Revenue by Company (2017-2022)
7.2 Europe Biosimilars of Rituximab Market Size by Type
7.2.1 Europe Biosimilars of Rituximab Sales by Type (2017-2028)
7.2.2 Europe Biosimilars of Rituximab Revenue by Type (2017-2028)
7.3 Europe Biosimilars of Rituximab Market Size by Application
7.3.1 Europe Biosimilars of Rituximab Sales by Application (2017-2028)
7.3.2 Europe Biosimilars of Rituximab Revenue by Application (2017-2028)
7.4 Europe Biosimilars of Rituximab Market Size by Country
7.4.1 Europe Biosimilars of Rituximab Sales by Country (2017-2028)
7.4.2 Europe Biosimilars of Rituximab Revenue by Country (2017-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Biosimilars of Rituximab Sales Breakdown by Company
8.1.1 Asia Pacific Biosimilars of Rituximab Sales by Company (2017-2022)
8.1.2 Asia Pacific Biosimilars of Rituximab Revenue by Company (2017-2022)
8.2 Asia Pacific Biosimilars of Rituximab Market Size by Type
8.2.1 Asia Pacific Biosimilars of Rituximab Sales by Type (2017-2028)
8.2.2 Asia Pacific Biosimilars of Rituximab Revenue by Type (2017-2028)
8.3 Asia Pacific Biosimilars of Rituximab Market Size by Application
8.3.1 Asia Pacific Biosimilars of Rituximab Sales by Application (2017-2028)
8.3.2 Asia Pacific Biosimilars of Rituximab Revenue by Application (2017-2028)
8.4 Asia Pacific Biosimilars of Rituximab Market Size by Region
8.4.1 Asia Pacific Biosimilars of Rituximab Sales by Region
8.4.2 Asia Pacific Biosimilars of Rituximab Revenue by Region
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 China Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
9 Latin America
9.1 Latin America Biosimilars of Rituximab Sales Breakdown by Company
9.1.1 Latin America Biosimilars of Rituximab Sales by Company (2017-2022)
9.1.2 Latin America Biosimilars of Rituximab Revenue by Company (2017-2022)
9.2 Latin America Biosimilars of Rituximab Market Size by Type
9.2.1 Latin America Biosimilars of Rituximab Sales by Type (2017-2028)
9.2.2 Latin America Biosimilars of Rituximab Revenue by Type (2017-2028)
9.3 Latin America Biosimilars of Rituximab Market Size by Application
9.3.1 Latin America Biosimilars of Rituximab Sales by Application (2017-2028)
9.3.2 Latin America Biosimilars of Rituximab Revenue by Application (2017-2028)
9.4 Latin America Biosimilars of Rituximab Market Size by Country
9.4.1 Latin America Biosimilars of Rituximab Sales by Country (2017-2028)
9.4.2 Latin America Biosimilars of Rituximab Revenue by Country (2017-2028)
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Biosimilars of Rituximab Sales Breakdown by Company
10.1.1 Middle East and Africa Biosimilars of Rituximab Sales by Company (2017-2022)
10.1.2 Middle East and Africa Biosimilars of Rituximab Revenue by Company (2017-2022)
10.2 Middle East and Africa Biosimilars of Rituximab Market Size by Type
10.2.1 Middle East and Africa Biosimilars of Rituximab Sales by Type (2017-2028)
10.2.2 Middle East and Africa Biosimilars of Rituximab Revenue by Type (2017-2028)
10.3 Middle East and Africa Biosimilars of Rituximab Market Size by Application
10.3.1 Middle East and Africa Biosimilars of Rituximab Sales by Application (2017-2028)
10.3.2 Middle East and Africa Biosimilars of Rituximab Revenue by Application (2017-2028)
10.4 Middle East and Africa Biosimilars of Rituximab Market Size by Country
10.4.1 Middle East and Africa Biosimilars of Rituximab Sales by Country (2017-2028)
10.4.2 Middle East and Africa Biosimilars of Rituximab Revenue by Country (2017-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Company Profiles
11.1 Amgen
11.1.1 Amgen Corporation Information
11.1.2 Amgen Overview
11.1.3 Amgen Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.1.4 Amgen Biosimilars of Rituximab Products and Services
11.1.5 Amgen Biosimilars of Rituximab SWOT Analysis
11.1.6 Amgen Recent Developments
11.2 AryoGen Pharmed
11.2.1 AryoGen Pharmed Corporation Information
11.2.2 AryoGen Pharmed Overview
11.2.3 AryoGen Pharmed Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.2.4 AryoGen Pharmed Biosimilars of Rituximab Products and Services
11.2.5 AryoGen Pharmed Biosimilars of Rituximab SWOT Analysis
11.2.6 AryoGen Pharmed Recent Developments
11.3 Biocad
11.3.1 Biocad Corporation Information
11.3.2 Biocad Overview
11.3.3 Biocad Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.3.4 Biocad Biosimilars of Rituximab Products and Services
11.3.5 Biocad Biosimilars of Rituximab SWOT Analysis
11.3.6 Biocad Recent Developments
11.4 Cadila Pharmaceuticals
11.4.1 Cadila Pharmaceuticals Corporation Information
11.4.2 Cadila Pharmaceuticals Overview
11.4.3 Cadila Pharmaceuticals Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.4.4 Cadila Pharmaceuticals Biosimilars of Rituximab Products and Services
11.4.5 Cadila Pharmaceuticals Biosimilars of Rituximab SWOT Analysis
11.4.6 Cadila Pharmaceuticals Recent Developments
11.5 Celltrion
11.5.1 Celltrion Corporation Information
11.5.2 Celltrion Overview
11.5.3 Celltrion Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.5.4 Celltrion Biosimilars of Rituximab Products and Services
11.5.5 Celltrion Biosimilars of Rituximab SWOT Analysis
11.5.6 Celltrion Recent Developments
11.6 Dr Reddy's Laboratories
11.6.1 Dr Reddy's Laboratories Corporation Information
11.6.2 Dr Reddy's Laboratories Overview
11.6.3 Dr Reddy's Laboratories Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.6.4 Dr Reddy's Laboratories Biosimilars of Rituximab Products and Services
11.6.5 Dr Reddy's Laboratories Biosimilars of Rituximab SWOT Analysis
11.6.6 Dr Reddy's Laboratories Recent Developments
11.7 Teva
11.7.1 Teva Corporation Information
11.7.2 Teva Overview
11.7.3 Teva Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.7.4 Teva Biosimilars of Rituximab Products and Services
11.7.5 Teva Biosimilars of Rituximab SWOT Analysis
11.7.6 Teva Recent Developments
11.8 Hetero Group
11.8.1 Hetero Group Corporation Information
11.8.2 Hetero Group Overview
11.8.3 Hetero Group Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.8.4 Hetero Group Biosimilars of Rituximab Products and Services
11.8.5 Hetero Group Biosimilars of Rituximab SWOT Analysis
11.8.6 Hetero Group Recent Developments
11.9 Innovent Biologics
11.9.1 Innovent Biologics Corporation Information
11.9.2 Innovent Biologics Overview
11.9.3 Innovent Biologics Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.9.4 Innovent Biologics Biosimilars of Rituximab Products and Services
11.9.5 Innovent Biologics Biosimilars of Rituximab SWOT Analysis
11.9.6 Innovent Biologics Recent Developments
11.10 Intas Biopharmaceuticals
11.10.1 Intas Biopharmaceuticals Corporation Information
11.10.2 Intas Biopharmaceuticals Overview
11.10.3 Intas Biopharmaceuticals Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.10.4 Intas Biopharmaceuticals Biosimilars of Rituximab Products and Services
11.10.5 Intas Biopharmaceuticals Biosimilars of Rituximab SWOT Analysis
11.10.6 Intas Biopharmaceuticals Recent Developments
11.11 Mylan
11.11.1 Mylan Corporation Information
11.11.2 Mylan Overview
11.11.3 Mylan Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.11.4 Mylan Biosimilars of Rituximab Products and Services
11.11.5 Mylan Recent Developments
11.12 Probiomed
11.12.1 Probiomed Corporation Information
11.12.2 Probiomed Overview
11.12.3 Probiomed Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.12.4 Probiomed Biosimilars of Rituximab Products and Services
11.12.5 Probiomed Recent Developments
11.13 TRPharma
11.13.1 TRPharma Corporation Information
11.13.2 TRPharma Overview
11.13.3 TRPharma Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.13.4 TRPharma Biosimilars of Rituximab Products and Services
11.13.5 TRPharma Recent Developments
11.14 Zenotech Laboratories
11.14.1 Zenotech Laboratories Corporation Information
11.14.2 Zenotech Laboratories Overview
11.14.3 Zenotech Laboratories Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.14.4 Zenotech Laboratories Biosimilars of Rituximab Products and Services
11.14.5 Zenotech Laboratories Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Biosimilars of Rituximab Value Chain Analysis
12.2 Biosimilars of Rituximab Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Biosimilars of Rituximab Production Mode & Process
12.4 Biosimilars of Rituximab Sales and Marketing
12.4.1 Biosimilars of Rituximab Sales Channels
12.4.2 Biosimilars of Rituximab Distributors
12.5 Biosimilars of Rituximab Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
List of TablesTable 1. Global Biosimilars of Rituximab Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of 500mg
Table 3. Major Manufacturers of 100mg
Table 4. Major Manufacturers of Other
Table 5. Global Biosimilars of Rituximab Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Biosimilars of Rituximab Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
Table 7. Global Biosimilars of Rituximab Sales by Region (2017-2022) & (K Units)
Table 8. Global Biosimilars of Rituximab Sales Market Share by Region (2017-2022)
Table 9. Global Biosimilars of Rituximab Revenue by Region (2017-2022) & (US$ Million)
Table 10. Global Biosimilars of Rituximab Revenue Market Share by Region (2017-2022)
Table 11. Global Biosimilars of Rituximab Sales Forecast by Region (2023-2028) & (K Units)
Table 12. Global Biosimilars of Rituximab Sales Market Share Forecast by Region (2023-2028)
Table 13. Global Biosimilars of Rituximab Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 14. Global Biosimilars of Rituximab Revenue Market Share Forecast by Region (2023-2028)
Table 15. Top Biosimilars of Rituximab Regions (Countries) Ranking by Market Size (US$ Million) in 2021
Table 16. Biosimilars of Rituximab Market Trends
Table 17. Biosimilars of Rituximab Market Drivers
Table 18. Biosimilars of Rituximab Market Challenges
Table 19. Biosimilars of Rituximab Market Restraints
Table 20. Global Biosimilars of Rituximab Sales by Manufacturers (2017-2022) & (K Units)
Table 21. Global Biosimilars of Rituximab Sales Share by Manufacturers (2017-2022)
Table 22. Global Biosimilars of Rituximab Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 23. Ranking of Global Top Biosimilars of Rituximab Manufacturers by Revenue (US$ Million) in 2021
Table 24. Biosimilars of Rituximab Revenue Share by Manufacturers (2017-2022)
Table 25. Global Biosimilars of Rituximab Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 26. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Biosimilars of Rituximab as of 2021)
Table 27. Key Manufacturers Biosimilars of Rituximab Average Selling Price (ASP) & (2017-2022) & (US$/Unit)
Table 28. Key Manufacturers Biosimilars of Rituximab Plants/Factories Distribution
Table 29. Key Manufacturers Biosimilars of Rituximab Area Served
Table 30. Date of Key Manufacturers Enter into Biosimilars of Rituximab Market
Table 31. Key Manufacturers Biosimilars of Rituximab Product Type
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Biosimilars of Rituximab Sales (K Units) by Type (2017-2022)
Table 34. Global Biosimilars of Rituximab Sales Share by Type (2017-2022)
Table 35. Global Biosimilars of Rituximab Revenue (US$ Million) Market Share by Type (2017-2022)
Table 36. Global Biosimilars of Rituximab Price (K Units) by Type (2017-2022)
Table 37. Global Biosimilars of Rituximab Sales (K Units) by Type (2023-2028)
Table 38. Global Biosimilars of Rituximab Sales Share by Type (2023-2028)
Table 39. Global Biosimilars of Rituximab Revenue (US$ Million) Market Share by Type (2023-2028)
Table 40. Global Biosimilars of Rituximab Revenue Share by Type (2023-2028)
Table 41. Global Biosimilars of Rituximab Price (K Units) by Type (2023-2028)
Table 42. Global Biosimilars of Rituximab Sales (K Units) by Application (2017-2022)
Table 43. Global Biosimilars of Rituximab Sales Share by Application (2017-2022)
Table 44. Global Biosimilars of Rituximab Revenue (US$ Million) Market Share by Application (2017-2022)
Table 45. Global Biosimilars of Rituximab Price (K Units) by Application (2017-2022)
Table 46. Global Biosimilars of Rituximab Sales (K Units) by Application (2023-2028)
Table 47. Global Biosimilars of Rituximab Sales Share by Application (2023-2028)
Table 48. Global Biosimilars of Rituximab Revenue (US$ Million) Market Share by Application (2023-2028)
Table 49. Global Biosimilars of Rituximab Revenue Share by Application (2023-2028)
Table 50. Global Biosimilars of Rituximab Price (K Units) by Application (2023-2028)
Table 51. North America Biosimilars of Rituximab Sales by Company (2017-2022) & (K Units)
Table 52. North America Biosimilars of Rituximab Sales Market Share by Company (2017-2022)
Table 53. North America Biosimilars of Rituximab Revenue by Company (2017-2022) & (US$ Million)
Table 54. North America Biosimilars of Rituximab Revenue Market Share by Company (2017-2022)
Table 55. North America Biosimilars of Rituximab Sales by Type (2017-2022) & (K Units)
Table 56. North America Biosimilars of Rituximab Sales by Type (2023-2028) & (K Units)
Table 57. North America Biosimilars of Rituximab Revenue by Type (2017-2022) & (US$ Million)
Table 58. North America Biosimilars of Rituximab Revenue by Type (2023-2028) & (US$ Million)
Table 59. North America Biosimilars of Rituximab Sales by Application (2017-2022) & (K Units)
Table 60. North America Biosimilars of Rituximab Sales by Application (2023-2028) & (K Units)
Table 61. North America Biosimilars of Rituximab Revenue by Application (2017-2022) & (US$ Million)
Table 62. North America Biosimilars of Rituximab Revenue by Application (2023-2028) & (US$ Million)
Table 63. North America Biosimilars of Rituximab Sales by Country (2017-2022) & (K Units)
Table 64. North America Biosimilars of Rituximab Sales by Country (2023-2028) & (K Units)
Table 65. North America Biosimilars of Rituximab Revenue by Country (2017-2022) & (US$ Million)
Table 66. North America Biosimilars of Rituximab Revenue by Country (2023-2028) & (US$ Million)
Table 67. Europe Biosimilars of Rituximab Sales by Company (2017-2022) & (K Units)
Table 68. Europe Biosimilars of Rituximab Sales Market Share by Company (2017-2022)
Table 69. Europe Biosimilars of Rituximab Revenue by Company (2017-2022) & (US$ Million)
Table 70. Europe Biosimilars of Rituximab Revenue Market Share by Company (2017-2022)
Table 71. Europe Biosimilars of Rituximab Sales by Type (2017-2022) & (K Units)
Table 72. Europe Biosimilars of Rituximab Sales by Type (2023-2028) & (K Units)
Table 73. Europe Biosimilars of Rituximab Revenue by Type (2017-2022) & (US$ Million)
Table 74. Europe Biosimilars of Rituximab Revenue by Type (2023-2028) & (US$ Million)
Table 75. Europe Biosimilars of Rituximab Sales by Application (2017-2022) & (K Units)
Table 76. Europe Biosimilars of Rituximab Sales by Application (2023-2028) & (K Units)
Table 77. Europe Biosimilars of Rituximab Revenue by Application (2017-2022) & (US$ Million)
Table 78. Europe Biosimilars of Rituximab Revenue by Application (2023-2028) & (US$ Million)
Table 79. Europe Biosimilars of Rituximab Sales by Country (2017-2022) & (K Units)
Table 80. Europe Biosimilars of Rituximab Sales by Country (2023-2028) & (K Units)
Table 81. Europe Biosimilars of Rituximab Revenue by Country (2017-2022) & (US$ Million)
Table 82. Europe Biosimilars of Rituximab Revenue by Country (2023-2028) & (US$ Million)
Table 83. Asia Pacific Biosimilars of Rituximab Sales by Company (2017-2022) & (K Units)
Table 84. Asia Pacific Biosimilars of Rituximab Sales Market Share by Company (2017-2022)
Table 85. Asia Pacific Biosimilars of Rituximab Revenue by Company (2017-2022) & (US$ Million)
Table 86. Asia Pacific Biosimilars of Rituximab Revenue Market Share by Company (2017-2022)
Table 87. Asia Pacific Biosimilars of Rituximab Sales by Type (2017-2022) & (K Units)
Table 88. Asia Pacific Biosimilars of Rituximab Sales by Type (2023-2028) & (K Units)
Table 89. Asia Pacific Biosimilars of Rituximab Revenue by Type (2017-2022) & (US$ Million)
Table 90. Asia Pacific Biosimilars of Rituximab Revenue by Type (2023-2028) & (US$ Million)
Table 91. Asia Pacific Biosimilars of Rituximab Sales by Application (2017-2022) & (K Units)
Table 92. Asia Pacific Biosimilars of Rituximab Sales by Application (2023-2028) & (K Units)
Table 93. Asia Pacific Biosimilars of Rituximab Revenue by Application (2017-2022) & (US$ Million)
Table 94. Asia Pacific Biosimilars of Rituximab Revenue by Application (2023-2028) & (US$ Million)
Table 95. Asia Pacific Biosimilars of Rituximab Sales by Region (2017-2022) & (K Units)
Table 96. Asia Pacific Biosimilars of Rituximab Sales by Region (2023-2028) & (K Units)
Table 97. Asia Pacific Biosimilars of Rituximab Revenue by Region (2017-2022) & (US$ Million)
Table 98. Asia Pacific Biosimilars of Rituximab Revenue by Region (2023-2028) & (US$ Million)
Table 99. Latin America Biosimilars of Rituximab Sales by Company (2017-2022) & (K Units)
Table 100. Latin America Biosimilars of Rituximab Sales Market Share by Company (2017-2022)
Table 101. Latin America Biosimilars of Rituximab Revenue by Company (2017-2022) & (US$ Million)
Table 102. Latin America Biosimilars of Rituximab Revenue Market Share by Company (2017-2022)
Table 103. Latin America Biosimilars of Rituximab Sales by Type (2017-2022) & (K Units)
Table 104. Latin America Biosimilars of Rituximab Sales by Type (2023-2028) & (K Units)
Table 105. Latin America Biosimilars of Rituximab Revenue by Type (2017-2022) & (US$ Million)
Table 106. Latin America Biosimilars of Rituximab Revenue by Type (2023-2028) & (US$ Million)
Table 107. Latin America Biosimilars of Rituximab Sales by Application (2017-2022) & (K Units)
Table 108. Latin America Biosimilars of Rituximab Sales by Application (2023-2028) & (K Units)
Table 109. Latin America Biosimilars of Rituximab Revenue by Application (2017-2022) & (US$ Million)
Table 110. Latin America Biosimilars of Rituximab Revenue by Application (2023-2028) & (US$ Million)
Table 111. Latin America Biosimilars of Rituximab Sales by Country (2017-2022) & (K Units)
Table 112. Latin America Biosimilars of Rituximab Sales by Country (2023-2028) & (K Units)
Table 113. Latin America Biosimilars of Rituximab Revenue by Country (2017-2022) & (US$ Million)
Table 114. Latin America Biosimilars of Rituximab Revenue by Country (2023-2028) & (US$ Million)
Table 115. Middle East and Africa Biosimilars of Rituximab Sales by Company (2017-2022) & (K Units)
Table 116. Middle East and Africa Biosimilars of Rituximab Sales Market Share by Company (2017-2022)
Table 117. Middle East and Africa Biosimilars of Rituximab Revenue by Company (2017-2022) & (US$ Million)
Table 118. Middle East and Africa Biosimilars of Rituximab Revenue Market Share by Company (2017-2022)
Table 119. Middle East and Africa Biosimilars of Rituximab Sales by Type (2017-2022) & (K Units)
Table 120. Middle East and Africa Biosimilars of Rituximab Sales by Type (2023-2028) & (K Units)
Table 121. Middle East and Africa Biosimilars of Rituximab Revenue by Type (2017-2022) & (US$ Million)
Table 122. Middle East and Africa Biosimilars of Rituximab Revenue by Type (2023-2028) & (US$ Million)
Table 123. Middle East and Africa Biosimilars of Rituximab Sales by Application (2017-2022) & (K Units)
Table 124. Middle East and Africa Biosimilars of Rituximab Sales by Application (2023-2028) & (K Units)
Table 125. Middle East and Africa Biosimilars of Rituximab Revenue by Application (2017-2022) & (US$ Million)
Table 126. Middle East and Africa Biosimilars of Rituximab Revenue by Application (2023-2028) & (US$ Million)
Table 127. Middle East and Africa Biosimilars of Rituximab Sales by Country (2017-2022) & (K Units)
Table 128. Middle East and Africa Biosimilars of Rituximab Sales by Country (2023-2028) & (K Units)
Table 129. Middle East and Africa Biosimilars of Rituximab Revenue by Country (2017-2022) & (US$ Million)
Table 130. Middle East and Africa Biosimilars of Rituximab Revenue by Country (2023-2028) & (US$ Million)
Table 131. Amgen Corporation Information
Table 132. Amgen Description and Overview
Table 133. Amgen Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 134. Amgen Biosimilars of Rituximab Product and Services
Table 135. Amgen Biosimilars of Rituximab SWOT Analysis
Table 136. Amgen Recent Developments
Table 137. AryoGen Pharmed Corporation Information
Table 138. AryoGen Pharmed Description and Overview
Table 139. AryoGen Pharmed Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 140. AryoGen Pharmed Biosimilars of Rituximab Product and Services
Table 141. AryoGen Pharmed Biosimilars of Rituximab SWOT Analysis
Table 142. AryoGen Pharmed Recent Developments
Table 143. Biocad Corporation Information
Table 144. Biocad Description and Overview
Table 145. Biocad Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 146. Biocad Biosimilars of Rituximab Product and Services
Table 147. Biocad Biosimilars of Rituximab SWOT Analysis
Table 148. Biocad Recent Developments
Table 149. Cadila Pharmaceuticals Corporation Information
Table 150. Cadila Pharmaceuticals Description and Overview
Table 151. Cadila Pharmaceuticals Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 152. Cadila Pharmaceuticals Biosimilars of Rituximab Product and Services
Table 153. Cadila Pharmaceuticals Biosimilars of Rituximab SWOT Analysis
Table 154. Cadila Pharmaceuticals Recent Developments
Table 155. Celltrion Corporation Information
Table 156. Celltrion Description and Overview
Table 157. Celltrion Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 158. Celltrion Biosimilars of Rituximab Product and Services
Table 159. Celltrion Biosimilars of Rituximab SWOT Analysis
Table 160. Celltrion Recent Developments
Table 161. Dr Reddy's Laboratories Corporation Information
Table 162. Dr Reddy's Laboratories Description and Overview
Table 163. Dr Reddy's Laboratories Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 164. Dr Reddy's Laboratories Biosimilars of Rituximab Product and Services
Table 165. Dr Reddy's Laboratories Biosimilars of Rituximab SWOT Analysis
Table 166. Dr Reddy's Laboratories Recent Developments
Table 167. Teva Corporation Information
Table 168. Teva Description and Overview
Table 169. Teva Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 170. Teva Biosimilars of Rituximab Product and Services
Table 171. Teva Biosimilars of Rituximab SWOT Analysis
Table 172. Teva Recent Developments
Table 173. Hetero Group Corporation Information
Table 174. Hetero Group Description and Overview
Table 175. Hetero Group Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 176. Hetero Group Biosimilars of Rituximab Product and Services
Table 177. Hetero Group Biosimilars of Rituximab SWOT Analysis
Table 178. Hetero Group Recent Developments
Table 179. Innovent Biologics Corporation Information
Table 180. Innovent Biologics Description and Overview
Table 181. Innovent Biologics Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Tabl